# Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects

> **NCT05449535** · PHASE1 · COMPLETED · sponsor: **Jemincare** · enrollment: 56 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JYB1904
- **DRUG:** Omalizumab
- **DRUG:** JYB1904 Placebo

## Key facts

- **NCT ID:** NCT05449535
- **Lead sponsor:** Jemincare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-07
- **Primary completion:** 2023-01-10
- **Final completion:** 2023-01-10
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2023-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05449535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05449535, "Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05449535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*